Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study focuses on the evaluation of various factors repeatedly discussed in relation to the impaired sedation of intubated ventilated COVID-19 patients. The sedation response of >100 moderately to severely affected COVID-19 ARDS was evaluated. The sedation level was measured at the bedside using the Richmond Agitation and Sedation Scale and ventilator synchrony. The evaluation was performed according to the static evaluation plan with respect to age, storage therapy and organ failure.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| moderate to severe COVID-19 ARDS | patients with an oxygenation index <200 under intubation anesthesia and mechanical ventilation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Treatment group | Other | None, solely treatment documentation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Position therapy | Number of positioning therapys during treatment | Data collection is performed at the date of death from any cause or discharge up to 10 weeks. |
| Agitation and sedation level | Measurement is performed using the Richmond Agitation and Sedation Scale (RASS, range: -5[Unarousable] to +4 [Combative], normal condition=0 [Alert and calm]) | 30 minutes after study enrolment |
| Agitation and sedation level | Change of sedation level using the Richmond Agitation and Sedation Scale (RASS, range: -5[Unarousable] to +4 [Combative], normal condition=0 [Alert and calm]) | Change in average dosage within 8 hours. |
| Application of opioid analgesic | Applied dosage of sufentanil (measured in µg/kg/h) | 30 minutes after study enrolment |
| Change of application of opioid analgesic | Applied dosage of sufentanil (measured in µg/kg/h) | Change in average dosage within 8 hours. |
| Application of opioid analgesic | Applied dosage of remifentanil (measured in µg/kg/min) | 30 minutes after study enrolment |
| Change of application of opioid analgesic | Applied dosage of remifentanil (measured in µg/kg/min) | Change in average dosage within 8 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| Need for renal replacement therapy | The necessity and application of a renal replacement procedure is documented | Data collection is performed at the date of death from any cause or discharge up to 10 weeks. |
| Need for extracorporeal membrane oxygenation (vvECMO) |
Not provided
Inclusion Criteria:
moderate to severe COVID-19 ARDS
Exclusion Criteria:
None
Not provided
Not provided
Not provided
all patients admitted to the intensive care unit who were already diagnosed with (SARS-CoV-2) infection.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Armin N Flinspach, MD | KGU | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Frankfurt | Frankfurt am Main | Hesse | 60590 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| Application of sedative | Applied dosage of midazolam (measured in mg/kg/h) | 30 minutes after study enrolment |
| Change in sedative dosage applied | Applied dosage of midazolam (measured in mg/kg/h) | Change in average dosage within 8 hours. |
| Application of sedative | Applied dosage of propofol (measured in mg/kg/h) | 30 minutes after study enrolment |
| Change in sedative dosage applied | Applied dosage of propofol (measured in mg/kg/h) | Change in average dosage within 8 hours. |
| Application of sedative | Applied dosage of lormetazepam (measured in mg/kg/min) | 30 minutes after study enrolment |
| Change in sedative dosage applied | Applied dosage of lormetazepam (measured in mg/kg/min) | Change in average dosage within 8 hours. |
| Application of sedative | Applied dosage of clonidine (measured in µg/kg/h) | 30 minutes after study enrolment |
| Change in sedative dosage applied | Applied dosage of clonidine (measured in µg/kg/h) | Change in average dosage within 8 hours. |
| Application of sedative | Applied dosage of Dexmethomidine (measured in µg/kg/h) | 30 minutes after study enrolment |
| Change in sedative dosage applied | Applied dosage of Dexmethomidine (measured in µg/kg/h) | Change in average dosage within 8 hours. |
| Application of sedative | Applied dosage of esketamine (measured in mg/kg/h) | 30 minutes after study enrolment |
| Change in sedative dosage applied | Applied dosage of esketamine (measured in mg/kg/h) | Change in average dosage within 8 hours. |
| Patient Characteristics | Age (in years) | The data is recorded at the time of enrolment |
| Patient Characteristics | Height (in centimeters) | The data is recorded at the time of enrolment |
| Patient Characteristics | Weight (in kilograms) | The data is recorded at the time of enrolment |
The necessity and application of an extracorporeal oxygenation procedure (ECMO) is documented |
| Data collection is performed at the date of death from any cause or discharge up to 10 weeks. |